<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80516">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01746147</url>
  </required_header>
  <id_info>
    <org_study_id>ALLIVE-2012</org_study_id>
    <nct_id>NCT01746147</nct_id>
  </id_info>
  <brief_title>Assessment of Body, Liver and Labile Plasma Iron and Their Association With Outcome and Immunological Recovery in Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Stem Cell Transplantation - ALLIVE (ALLogeneic Iron inVEstigators) Observational Trial</brief_title>
  <acronym>ALLIVE</acronym>
  <official_title>Assessment of Body, Liver and Labile Plasma Iron and Their Association With Outcome and Immunological Recovery in MDS or AML Patients Undergoing Allogeneic Stem Cell Transplantation - ALLIVE (ALLogeneic Iron inVEstigators) Observational Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GWT-TUD GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GWT-TUD GmbH</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ALLIVE (ALLogeneic Iron inVEstigators) trial aims at quantifying the extent and dynamic
      change of LPI occurrence during conditioning and at identifying LPI-predictive
      peri-transplant parameters. Further points of interest are the improvement of systemic iron
      overload (SIO) diagnostics and the correlation of different SIO parameters with outcome
      after transplantation. The results of this trial will help to design prospective
      interventional studies addressing therapeutic options in patients at risk for SIO-associated
      toxicity during allogeneic stem-cell transplantation (allo-SCT).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Description of dynamic changes of LPI prior, during and after conditioning for allo-SCT using standard descriptive parameters (Mean or Median and appropriate confidence intervals)</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Correlation coefficient of Liver iron concentration (LIC) and duration of detectable LPI during and after conditioning</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Area under the Receiver-Operator-Characteristic (ROC) as well as sensitivity and specificity of specific thresholds of serum ferritin and transfusion history for prediction of LIC</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Association of serum ferritin and LIC with hematopoietic cell transplantation comorbidity index (HCT-CI)</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Time course of LPI, enhanced labile plasma iron (eLPI), directly chelatable iron (DCI) and hepcidin during allo-SCT</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Association of detectable LPI or eLPI during conditioning and occurrence of elevated liver enzymes during in hospital treatment course for allo-SCT</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Cumulative incidence of graft versus host disease (aGvHD) grade 2-4 with respect to serum ferritin &gt;1000 µg/l, transfusion burden &gt;20 units of Red blood cells (RBC), LIC &gt;125 µmol/g, peak value and duration of detectable labile plasma iron above median</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Cumulative incidence of day 100 non-relapse mortality (NRM) with respect to serum ferritin &gt;1000 µg/l, transfusion burden &gt;20 units of RBC, LIC &gt;125 µmol/g and peak value and duration of detectable labile plasma iron above median</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Cumulative incidence of infections with respect to serum ferritin &gt;1000 µg/l, transfusion burden &gt;20 parasitized red blood cell (PRBC), LIC &gt;125 µmol/g and peak value and duration of detectable labile plasma iron above median</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Median change of serum ferritin and LIC 100 days and 1 year after allo-SCT</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Association between immune profile and iron parameters (serum ferritin &gt;1000 µg/l, transfusion burden &gt;20 units RBC, LIC &gt;90 µmol/g and peak value and duration of detectable labile plasma iron above median</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">134</enrollment>
  <condition>MDS and AML Prior to Allogeneic SCT</condition>
  <arm_group>
    <arm_group_label>Patients with MDS and AML prior to allogeneic SCT</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention and study treatment</intervention_name>
    <arm_group_label>Patients with MDS and AML prior to allogeneic SCT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Men and women with AML or MDS according to WHO classification.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 18 years at the time of signing the informed consent form

          -  Signed informed consent

          -  Diagnosis of AML or MDS according to WHO classification

          -  Planned allogeneic stem cell transplantation after reduced intensity or myeloablative
             conditioning from related or unrelated donors

          -  At risk for iron toxicity as defined by ferritin &gt;500 ng/ml and/or history of more
             than 10 RBC transfusions prior to allo-SCT

        Exclusion Criteria:

          -  Claustrophobia or other mental disorders making MRI imaging unbearable for the
             patient

          -  Cardiac pacemakers, metal implants splinters or other contraindications for MRI

          -  More than 1 Human leukocyte antigen (HLA) allele or antigen mismatch between donor
             and recipient

          -  Any condition, including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study or confounds
             the ability to interpret data from the study

          -  Patients with a history of chronic drug abuse or another illness which does not allow
             the patient to assess the nature and/or possible consequences of the study

          -  Patients who are not likely to follow the trial protocol (lack of willingness to
             cooperate)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Wemke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>on behalf of GWT</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudia Spielau, Dr.</last_name>
    <phone>0351 25933 123</phone>
    <email>Claudia.Spielau@gwtonline.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>III. Medizinischen Klinik Hämatologie und Internistische Onkologie Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Klein, Dr.</last_name>
      <phone>0621 - 383-4116</phone>
      <email>heike.weiss@umm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>III. Medizinischen Klinik des Klinikums rechts der Isar</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katharina Götze, Dr.</last_name>
      <phone>089 - 4140-5618</phone>
      <email>k.goetze@lrz.tu-muenchen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik III Abteilung für Hämatologie und Onkologie Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominik Wolf, Prof. Dr.</last_name>
      <phone>0228 287 17233</phone>
      <email>dominik.wolf@ukb.uni-bonn.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus der TU Dresden Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Wermke, Dr</last_name>
      <phone>0351 458-15624</phone>
      <email>Martin.Wermke@uniklinikum-dresden.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 10, 2012</lastchanged_date>
  <firstreceived_date>December 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MDS</keyword>
  <keyword>AML</keyword>
  <keyword>allogeneic SCT</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
